Drugs / ASN007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03415126 | Jan 2018 → Jun 2020 | colon carcinoma, metastasis from malignant tumor of colon, metastatic melanoma, non-small cell lung carcinoma +1 | Asana BioSciences | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2018-10-29 | Asana BioSciences | Results CEOCFO Magazine Conducts Interview with Dr. Sandeep Gupta, Founder, President and CEO of Asana BioSciences asanabio.com ↗
It showed strong anti-proliferative activity in both BRAF and RAS mutant cell lines, as well as potent anti-proliferative activity in a number of KRAS, NRAS and HRAS mutant cell lines representing various histological tumor types. |
| 2018-01-03 | Asana BioSciences | Regulatory Asana BioSciences Announces Acceptance of IND Application for Its Oral ERK1/2 Inhibitor asanabio.com ↗ |
| 2017-10-24 | Asana BioSciences | Results Asana BioSciences to Present Updates on its Oncology Development Pipeline at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics asanabio.com ↗
ASN007, a novel oral ERK1/2 inhibitor, shows robust antitumor activity in RAS mutant cancer models. |
All press releases naming this drug 6 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASN007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03415126 ↗ |
| Modality | Small molecule | — CHEMBL4650280 ↗ |
| Route | Oral | “Oral drug for the treatment of advanced solid tumors” NCT03415126 ↗ |